Robert Davidson
Robert Davidson
Robert is Managing Editor of Applied Clinical Trials magazine. He received his B.S. degree in Magazine Journalism from the University of Maryland, College Park. Robert has significant experience in medical/scientific peer-review publishing, including a number of years with the IEEE Journals Department, where he managed 15 titles such as Transactions on Medical Imaging and Transactions on Nuclear Science. Earlier, he was an editorial researcher with National Magazine Award-winning IEEE Spectrum magazine. In 2003, he wrote a CME monograph covering COPD that was sponsored by GlaxoSmithKline. He has been with ACT for the past 3 years. In between his time with trade publications, Robert combined a personal interest and avocation as an editor with Field & Stream magazine, and he later gained public relations experience as a PR manager with Cendant Corporation.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
